Abstract | OBJECTIVES: METHODS: A multicentre retrospective analysis of patients with ILD secondary to SYN (n=15), MCTD (n=6) and SSc (n=23). PFTs were performed at baseline and at 1 and 2 years of follow-up. The primary outcome was the change in forced vital capacity (FVC) at 1 year. RESULTS: In the SYN population, median FVC changed from 53.0% (42.0-90.0) at baseline to 51.4% (45.6-85.0) at 1 year and 63.0 (50-88) (p=0.6) at 2 years (p=0.14). In SSc, FVC changed from 81.0% (66.0-104.0) at baseline to 89.0% (65.0-113.0) at 1 year (p=0.1) and 74.5 (50-91) at 2 years (p=0.07). In the MCTD population, FVC changed from 64.5% (63.0-68.0) at baseline to 63.0% (59.0-71.0) at 1 year (p=0.6) and 61 (59-71) after 2 years (p=0.8). DLCO showed a trend for improvement in the SYN population (p=0.06 at 1 year and 0.2 at years) while changes remain non-significant in the SSc and MCTD patients. In SYN patients, the percentage of responders at 1 year for FVC (33.3%) was greater than in SSc (9.5%) (p=0.07) and MCTD (17%) (p=0.45). RTX showed a satisfactory safety profile. CONCLUSIONS: A trend of improvement of PFTs was observed in SYN patients although not reaching significance, while SSc and MCTD patients were stabilised.
|
Authors | Gemma Lepri, Jerome Avouac, Paolo Airò, Francisco Anguita Santos, Silvia Bellando-Randone, Jelena Blagojevic, Francisco Garcia Hernàndez, Jose Antonio Gonzalez Nieto, Serena Guiducci, Suzana Jordan, Vidya Limaye, Britta Maurer, Albert Selva-O'Callaghan, Valeria Riccieri, Oliver Distler, Marco Matucci-Cerinic, Yannick Allanore |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2016 Sep-Oct
Vol. 34 Suppl 100
Issue 5
Pg. 181-185
ISSN: 0392-856X [Print] Italy |
PMID | 27749242
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Immunosuppressive Agents
- Rituximab
|
Topics |
- Adult
- Aged
- Connective Tissue Diseases
(complications, diagnosis, drug therapy)
- Disease Progression
- Female
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Lung
(drug effects, physiopathology)
- Lung Diseases, Interstitial
(diagnosis, drug therapy, etiology, physiopathology)
- Male
- Middle Aged
- Recovery of Function
- Respiratory Function Tests
- Retrospective Studies
- Rituximab
(adverse effects, therapeutic use)
- Time Factors
- Treatment Outcome
- Vital Capacity
|